Top Markets
Coin of the day
Organicell Regenerative Medicine, Inc. Organicell Regenerative Medicine, Inc.

Organicell Regenerative Medicine, Inc.

OCEL
Peringkat dalam Saham #31530
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical... Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNAs, without the inclusion of any artificial additives or diluents. Zofin is currently undergoing Phase I/II clinical evaluation for its efficacy against COVID-19. Beyond its core drug development, Organicell also offers independent educational, promotional, and marketing solutions to various healthcare sectors, including medical, anti-aging, and regenerative service providers. The company maintains key research collaborations: one with the Centers for Disease Control and Prevention (CDC) to explore Zofin's anti-inflammatory and anti-infective capabilities in experimental influenza models, and another with Oklahoma State University to assess Zofin's potential in treating severe respiratory illnesses stemming from viruses with pandemic risk. Founded in 2011, this Miami, Florida-based company initially operated as Biotech Products Services and Research, Inc. It adopted its current name, Organicell Regenerative Medicine, Inc., in June 2018.
Harga Saham
$1.77
Terakhir disinkronkan: 2024-04-02
Kapitalisasi Pasar
$12.89M
Perubahan (1 hari)
-11.50%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Organicell Regenerative Medicine, Inc. (OCEL)

Kategori

Rasio P/S untuk Organicell Regenerative Medicine, Inc. (OCEL)
Rasio P/S per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Organicell Regenerative Medicine, Inc., rasio P/S saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/S perusahaan adalah 0.
Riwayat rasio P/S untuk Organicell Regenerative Medicine, Inc. dari 2026 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
4.74 -
BE